Merdury Biopharmaceutical Corporation
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Merdury offers custom drug formulation and manufacturing services based on its StackDose™ platform — including formulation design, small‑scale prototyping, development of specialized tablet structures, and 3D‑printing mass‑production — and licenses its te
The content above was translated by Ai
Founded Year
2019
Unified Business No.
82959747
Status
Active
Number of Employees
19
Total Paid-in
Capital
108,149,026 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2022)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Merdury Biopharmaceutical Corporation, founded in 2019, is a pharmaceutical company dedicated to leveraging advanced 3D powder‑printing processes to innovate drug formulation and manufacturing; through its proprietary StackDose™ platform, it aims to develop and produce next‑generation specialty dosage drugs — pushing pharmaceutical technology forward with precision release and high added‑value medicine.
The content above was translated by Ai
